Mesenchymal Stromal Cells (MSCs) are being developed as a transfusional product to treat immune and inflammatory disorders. However, results of industry-sponsored randomized clinical trials that have utilized MSC-like cells have not met primary end points of efficacy for treatment of GvHD or inflammatory bowel disease. A better understanding of MSC mechanism of action would best inform future development strategies. MSC's immunosuppressive potential is markedly augmented by licensing by the proinflammatory cytokine, IFNγ. In the present review, we analyze the effect of MSC preparation methods on MSC's responsiveness to IFNγ and immune plasticity. The concept of prelicensing with IFNγ on MSC's immunosuppressive, engraftment and therapeutic potential is also discussed.
Introduction
Mesenchymal Stromal Cells (MSCs) are under intensive clinical investigation for the treatment of immune disorders and regenerative medicine, as evidenced by more than 300 registered clinical trials (clinicaltrials.gov). MSCs can be isolated from heart, dental pulp, umbilical cord blood, placenta, and peripheral blood, while the best characterized are derived from bone marrow and adipose tissue. Minimal criteria required for defining "multipotent MSC populations" iused in cell therapy are: (1) adherence to tissue culture plate, (2) cell surface expression of CD73, CD90, CD105, (3) lack of expression of CD45, CD34, CD14, CD11b, CD79a, CD19, HLADR and, (4) ability to differentiate into osteoblasts, adipocytes and chondroblasts under appropriate stimuli 1) . MSCs are present at low frequency (0.01 to 0.001 % of nucleated cells) in bone marrow. However, their robust in vitro proliferative potential by standard cell culture conditions facilitates their 3, 4) .
A large series of early phase clinical trials have demonstrated that MSCs are safe, but proof of therapeutic benefit by randomized clinical trials is lacking 5) . A large industry sponsored multicenter phase III randomized clinical trial demonstrated that MSC therapy (Prochymal; Osiris Therapeutics, Inc., Columbia, MD, USA) failed to meet the efficacy criteria for the treatment of steroid refractory acute graft-versus-host disease (GvHD) 6) . Another randomized Phase II study by Athersys, Inc. announced that their "offthe-shelf" allogenic, MultiStem ® , failed to show efficacy in patients with ulcerative colitis (http://www.athersys.com).
Considering the discrepancy between encouraging preclinical efficacy data and negative outcomes of these clinical studies, a better understanding of MSC biology may inform development strategies. In particular, MSC responsiveness to host inflammatory cues may provide novel translational insights. IFNγ is a well-studied immunomodulatory cytokine which modulates the immunobiology of MSCs 7, 8) and the in vivo suppressive properties of MSCs are likely dependent on licensing with endogenous IFNγ. The word "license" was first used by Lanzavecchia to describe the activation of APCs by T helper cells and other stimuli, which subsequently can stimulate cytotoxic killer T cells 9) . The process of licensing APCs by T helper cell is crucial to activate killer T cells. Similarly, IFNγ secreted by lymphoid effector cells is necessary to "license" MSCs to execute immune suppression. In addition, for future secondgeneration MSC-based therapies this naturally occurring in vivo licensing process can be pre-empted through prelicensing or pretreatment with IFNγ before infusion therapy. Moreover, MSC's responsiveness to IFNγ and the deployed immune activated signals such as IDO (Indoleamine 2,3-dioxygenase) is amenable to analysis and may be predictive of product potency 10) . Taking this analytic approach as a surrogate of in vivo MSC function, it may allow for comparison of methods used in MSC preparations for cell therapy. and, (4) IFNγ licensing is crucial for MSCs to suppress T cell effector functions 14) . All these studies suggest that 15) . IFNγ also upregulates MHC Class I and Class II on MSCs which enable them to cross-present soluble exogenous antigens to T cells like Antigen Presenting Cells (APCs) 16, 17) . However MSCs differ from professional APCs such as dendritic cells not only by lacking co-stimulatory molecules B7-1(CD80) and B7-2(CD86) but also IFNγ fails to upregulate them 14) . IFNγ inducible IDO expression plays a major role in MSC's immunosuppressive properties and defines an important component of MSC immune plasticity.
MSC responsiveness to IFNγ instructs T cell fate

IDO catabolizes conversion of tryptophan to kynurenine,
which is an inhibitor of T cell proliferation. Blocking IDO catabolic activity with 1-methyl tryptophan abolishes
MSC's suppressive activity on T cell proliferation in vitro.
Another tryptophan degrading enzyme, Tryptophan 2,3 dioxygenase (TDO) has homeostatic, housekeeping role predominantly in the liver and unlike IDO does not respond to immunoactive signals 18) . Human MSCs were shown to express TDO in the resting stage and IFNγ stimulation does not upregulate its expression 19, 20) . This suggests the leading 
Translational aspects of MSC's responsiveness to IFNγ
Multiple immunoregulatory molecules are produced by that MSCs do not form ectopic tissue 24) . In addition, HSCs home to bone marrow and engraft a feature that transfused MSCs do not possess 25) . More importantly, we have shown that thawed MSCs display impaired immunosuppressive and homing properties. Indeed, thawed MSCs undergo a molecular heat shock response by upregulating HSP70A and HSP70B proteins, which reflect a cellular response to injury and stress. Our studies also demonstrate that thawed MSCs display impaired responsiveness to IFNγ stimulation by exhibiting attenuated STAT-1 phosphorylation 26) . In a preclinical animal model of colitis, intravenously transfused cryopreserved allogeneic MSCs had no beneficial effect 27) .
In support of this, we have found that thawing induces
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MSC cytoskeleton disruption with marked effects on biodistribution pattern in vivo 28) . Thawing compromises cell viability by at least 10-15% and we had demonstrated that dead cells do not engraft and do not interfere with the engraftment of live cells. Thus thawing induces injury to live cells, which disables their intrinsic ability to mediate immune suppression and engraftment. These defects are reversible within approximately 24-48 hours if cells are allowed to recover post-thaw in culture media 28) . In support of this, a recent clinical trial has demonstrated that 100% of the patients respond to treatment with early passage fresh MSC product while only 50% of the comparable patient populations show responsiveness to late passage frozen MSC treatment 29) . This is the first translational evidence, which demonstrate the clinical benefit of using fresh MSCs and reduced telomere length 30, 31) . In comparison to actively growing human MSCs, senescent cells fail to control lethal endotoxemia in animals and senescent MSCs do not inhibit lymphocyte proliferation efficiently and display migratory defects in response to proinflammatory signals 32) .
It is unknown whether replicative senescent MSCs have
intact IFNγ responsive machinery akin to early passage MSCs. Late passage MSCs are clinically less effective in ameliorating GVHD than the earlier passage MSCs 33) .
However in an another clinical trial, difference in the clinical benefit was not observed between the treatment groups with MSCs from earlier and late passages 34) . As authors pointed out, the derivation of meaningful MSC effect in the setting of combination therapy is complex and more studies are required for the conclusion. Human fibroblasts, normal and tumorigenic epithelial cells become proinflammatory upon replicative senescence by acquiring a Senescence Associated Secretory Phenotype (SASP). The characteristic of SASP is the secretion of proinflammatory cytokines such as IL6, IL8 and GMCSF 35) . Thus further studies are required to determine whether senescent MSCs acquire a proinflammatory SASP-like phenotype and secretome.
Culture expansion conditions can also influence the senescent behavior of MSCs since fetal calf serum can induce senescence relatively faster than the human platelet lysate culture conditions 36) . In addition, chemical analogues have been shown to increase the immunosuppressive properties of replication impaired MSCs 37) . It will be of future interest to characterize whether such molecules may rescue MSCs from high passage senescence.
2)Host Inflammatory Milieu and in vivo licensing of
MSCs
Upon transfusion MSCs can be licensed by IFNγ derived from host lymphoid effector cells and deploy immunosuppressive properties 13) . Therapeutic efficacy of MSC was lost in a GVHD model when IFNγ KO donor T cells were used to induce the onset disease 38) . In a reciprocal experiment, it was shown that IFNγ receptor knock out MSCs do not exhibit any therapeutic activity against GVHD in mice, suggests that despite the presence of other synergistic cytokines, IFNγ licensing in situ is key for MSC mediated immune suppression 13) . In addition, in vitro studies demonstrate that the quantity of IFNγ determines MSC's proinflammatory and anti-inflammatory
properties. At low IFNγ concentrations, MSCs become
antigen-presenting cells while at the high concentrations they become suppressor cells 39) . Therefore, it is likely that the magnitude of available IFNγ but also the location of Another host factor, which may influence MSC biology, is the concurrent use of immunosuppressive drugs to suppress immune responses in autoimmune disorders.
MSCs have been shown to be act synergistically with mycophenolate mofetil and rapamycin to induce tolerance in solid organ transplantation models 42, 43) . Other common drugs used to treat inflammatory disorders such as azathioprine, methotrexate, 6-mercaptopurine and antitumor necrosis factor (TNF)-α, do not antagonize MSC's immunosuppressive properties 44) . In all these cases, immunosuppressive drugs act synergistically with MSC's immunosuppressive properties and no antagonism has been reported. on Day 0 45) . In addition, it has been demonstrated that the degree of GVHD mitigation is directly associated with the magnitude of MSC's pre exposure to IFNγ 38) .
Priming of MSCs with IFNγ for clinical use
Another study demonstrated that IFNγ pretreatment enhances MSC's capacity to inhibit Th1 inflammatory responses, resulting in diminished mucosal damage in experimental colitis 46) . These studies strongly suggest the benefit of utilizing MSCs pre-licensed with IFNγ. However, we have demonstrated that IFNγ licensed allogeneic MSCs lose their therapeutic activity against autoimmune encephalomyelitis (EAE) 47) . Considering that MSCs are not intrinsically immunoprivileged, random donor IFNγ licensed MSC are likely immune rejected by a host response to the upregulated expression of mismatched MHC class I and Class II molecules 48) . Thus, we speculate that IFNγ 
